A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Completed · Phase 2

Conditions studied: TTR-mediated Amyloidosis

In brief

The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.

Key facts

Study ID

NCT02292186

Run by

Alnylam Pharmaceuticals

People needed

25

Starts

2014-10-01

Expected to finish

2017-02-22

Last updated by the study team

2020-07-09

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the ALN-TTRSC-002 study
• Adequate liver function
• Not Pregnant or nursing

You may not qualify if…

• Inadequate renal function
• Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia
• Untreated hypo- or hyperthyroidism
• Prior major organ transplant

Where it is running

• Clinical Trial Site — Boston, Massachusetts, United States
• Clinical Trial Site — New York, New York, United States
• Clinical Trial Site — Cleveland, Ohio, United States
• Clinical Trial Site — Calgary, Alberta, Canada
• Clinical Trial Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.